Search Results 291-300 of 16005 for SC

  1. Publications - Lance A. Williams, III, M.D. - Mayo Clinic

    Simmons SC, Taylor LJ, Marques MB, Williams LA. Rat Poisoning: A Challenging Diagnosis With Clinical and Psychological Implications. Lab Med. 2018 Jul 5; 49 ...

  2. Lupus - Symptoms & causes - Mayo Clinic

    This is called an autoimmune condition. Lupus causes swelling and irritation, called inflammation, that may affect joints, skin, kidneys, blood cells, brain, ...

  3. Publications - Rick J. Bold, M.D., M.B.A. - Mayo Clinic

    ... SC, Kim KK. The Personal Health Network Mobile App for Chemotherapy Care Coordination: Qualitative Evaluation of a Randomized Clinical Trial. JMIR Mhealth ...

  4. Alumni - Bone and Soft Tissue Pathology Fellowship (Minnesota) - Mayo Clinic College of Medicine & Science

    Great Lakes Pathologist S.C., West Allis, WI. 2021, Judith Jebastin Thangaiah, M.B.B.S., Mayo Clinic, Rochester, MN. 2020, Nicholas Olson, M.D., Physicians ...

  5. Publications - Samir H. Patel, M.D. - Mayo Clinic

    ... SC, Gamez ME, Rwigema JM, Holtzman AL, Price DL, Janus JR, Kasperbauer JL ... SC, Ma DJ, McGee LA, Moore EJ, Neben Wittich MA, Patel SH, Routman DM ...

  6. Clinical trials - Oncology (Medical)

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  7. Contact us - Mayo Clinic

    SC: Mayo Clinic Breadcrumb. About Mayo Clinic · Mayo Clinic Care Network. Sections Mayo Clinic Care Network. Amplify expertise. Collapse Amplify expertise.

  8. Publications - John V. Murray, Jr., M.D. - Mayo Clinic

    Epub 2023 Apr 07. View PubMed; Philip JT, Flores MA, Beegle RD, Dodson SC, Messina SA, Murray JV Jr. Reply. AJNR Am J Neuroradiol 2023 Feb; 44 (2):E12 Epub ...

  9. A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease - Mayo Clinic

    The purpose of this study is to assess how safe and effective risankizumab subcutaneous (SC) induction treatment is in treating moderately to severely ...

  10. Oncology (Medical) - Clinical trials

    SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve ...